迈瑞医疗 (300760.SZ)

今开: 最高: 成交量:

昨收: 最低: 成交额:

+ 收藏

利润表(单季度)(迈瑞医疗)

导出到EXCEL
报表日期选择
  • 常用日期查询
  • 自定义年度查询
    日期范围
    报告期
    报告类型
    显示选项
关 闭
完整财报对比
2023年第三季度2023年第二季度2023年第一季度2022年第四季度2022年第三季度2022年第二季度2022年第一季度
上市前/上市后 上市后上市后上市后上市后上市后上市后上市后
报表类型 合并报表合并报表合并报表合并报表合并报表合并报表合并报表
一、营业总收入(元) 8,828,024,468.0010,111,491,655.008,364,281,841.007,069,813,142.007,940,254,590.008,412,467,085.006,943,108,994.00
 营业收入(元) 8,828,024,468.0010,111,491,655.008,364,281,841.007,069,813,142.007,940,254,590.008,412,467,085.006,943,108,994.00
二、营业总成本(元) 5,096,692,077.005,878,849,786.005,572,679,803.005,389,734,052.004,873,324,181.004,933,671,206.004,630,030,820.00
 营业成本(元) 2,894,866,984.003,545,548,896.002,810,679,041.002,568,934,921.002,808,330,239.003,085,034,103.002,422,990,195.00
 研发费用(元) 657,494,124.00999,128,774.00852,300,844.00835,234,558.00737,297,164.00646,137,211.00703,945,494.00
 营业税金及附加(元) 102,831,057.00100,534,525.0084,671,723.0094,520,922.0095,839,706.0078,476,139.0079,449,251.00
 销售费用(元) 1,154,783,744.001,460,762,395.001,373,819,628.001,471,089,206.001,178,429,824.001,079,086,175.001,072,950,119.00
 管理费用(元) 320,152,572.00338,556,237.00457,084,878.00389,161,797.00312,078,416.00260,435,487.00358,376,634.00
 财务费用(元) -33,436,404.00-565,681,041.00-5,876,311.0030,792,648.00-258,651,168.00-215,497,909.00-7,680,873.00
  其中:利息费用(元) 3,272,936.002,944,179.002,600,912.003,065,654.002,807,399.002,555,050.002,258,677.00
  其中:利息收入(元) 234,122,935.00153,776,909.00138,435,482.00104,698,454.0078,736,530.0085,872,762.0088,598,038.00
 资产减值损失(元) -43,199,370.00-34,297,752.00-42,555,992.00-22,826,804.00-19,749,751.00-8,013,755.00-20,503,792.00
 信用减值损失(元) -3,546,794.00-9,548,474.00-47,319,982.00-26,567,757.00-3,551,378.00-1,664,433.00-5,030,639.00
三、其他经营收益
 加:公允价值变动收益(元) 27,660,826.00-----29,203,624.007,825,435.00
 加:投资收益(元) -3,152,613.00-706,579.00-1,091,341.00-1,084,263.00-1,401,170.00-1,403,482.00-1,172,501.00
  其中:对联营企业和合营企业的投资收益(元) -3,481,413.00-451,134.00-1,091,341.00-720,726.00-1,401,170.00-1,403,482.00-1,172,501.00
 资产处置收益(元) 4,433,382.00480,706.00-594,324.0088,262.005,311,602.007,423,747.00-6,659,319.00
 其他收益(元) 157,195,812.00208,537,483.00199,644,189.00141,736,400.00166,287,221.00157,793,189.00113,998,291.00
四、营业利润(元) 3,870,723,634.004,430,283,459.002,899,684,588.001,771,424,928.003,213,826,933.003,603,727,521.002,401,535,649.00
 加:营业外收入(元) 17,952,112.009,102,517.009,074,442.007,326,936.0011,938,900.0010,904,898.005,112,409.00
 减:营业外支出(元) 11,484,033.0017,194,949.0021,158,655.0053,473,077.005,715,184.0012,117,309.00941,951.00
五、利润总额(元) 3,877,191,713.004,422,191,027.002,887,600,375.001,725,278,787.003,220,050,649.003,602,515,110.002,405,706,107.00
 减:所得税费用(元) 484,878,622.00551,317,451.00315,261,372.00220,346,785.00404,550,599.00419,203,029.00298,733,425.00
六、净利润(元) 3,392,313,091.003,870,873,576.002,572,339,003.001,504,932,002.002,815,500,050.003,183,312,081.002,106,972,682.00
(一)按经营持续性分类
  持续经营净利润(元) 3,392,313,091.003,870,873,576.002,572,339,003.001,504,932,002.002,815,500,050.003,183,312,081.002,106,972,682.00
(二)按所有权归属分类
  归属于母公司股东的净利润(元) 3,392,313,091.003,870,873,576.002,571,117,273.001,504,840,022.002,814,681,784.003,182,580,387.002,105,071,901.00
  少数股东损益(元) --1,221,730.0091,980.00818,266.00731,694.001,900,781.00
 扣除非经常性损益后的净利润(元) 3,345,234,570.003,811,570,281.002,529,128,371.001,521,438,107.002,756,585,765.003,174,908,759.002,072,184,897.00
七、每股收益
 一、基本每股收益(元) 2.803.192.131.242.332.631.74
 二、稀释每股收益(元) 2.803.192.121.242.332.631.74
八、其他综合收益(元) -123,046,158.00317,031,536.005,136,437.00175,799,198.0093,446,642.00112,945,106.00-81,520,698.00
 归属于母公司股东的其他综合收益(元) -123,046,158.00317,031,536.005,136,437.00175,799,198.0093,446,642.00112,945,106.00-81,520,698.00
九、综合收益总额(元) 3,269,266,933.004,187,905,112.002,577,475,440.001,680,731,200.002,908,946,692.003,296,257,187.002,025,451,984.00
 归属于母公司所有者的综合收益总额(元) 3,269,266,933.004,187,905,112.002,576,253,710.001,680,639,220.002,908,128,426.003,295,525,493.002,023,551,203.00
 归属于少数股东的综合收益总额(元) --1,221,730.0091,980.00818,266.00731,694.001,900,781.00
公告日期 2023-10-282023-08-302023-04-282023-04-282022-10-282022-08-202022-04-20
审计意见(境内) 标准无保留意见

前瞻产业研究院